

Changing the course of cardiovascular disease

Managing heart failure and lipid patients



With around 1.3 million Australians having a condition related to heart, stroke or vascular disease,¹ managing cardiovascular (CV) risk lies at the heart of primary practice.

With this in mind, we are delighted to invite you to join our in-person educational meeting, **Changing the course of cardiovascular disease: Managing heart failure and lipid patients**. This event will focus on the management of two key groups of patients: heart failure patients with residual risk, and patients with elevated LDL-C.


Australian experts will discuss the course of CVD, review current management options, and provide practical approaches for identifying and managing patients through case-based discussion.

Heart failure and lipid patients represent an important opportunity to change the disease trajectory. Join us to learn more about what you can do to change the course of disease for your patients with CVD.



**Register your
attendance today
to secure your spot**

About your speakers



Agenda

Time	Session
5 min	Welcome and introduction
30 min	Optimising HFrEF therapy: How can we reduce residual risk?
10 min	Patient case studies
15 min	Q&A
30 min	Targeting LDL-C - Why is it important?
10 min	Patient case studies
15 min	Q&A
5 min	Close

RSVP by For any questions regarding the meeting, please contact



CV, cardiovascular; CVD, cardiovascular disease; HFrEF, heart failure with reduced ejection fraction; LDL-C, low-density lipoprotein cholesterol.

Reference: 1. Australian Institute of Health and Welfare. 2024. Heart, stroke and vascular disease: Australian facts. Available at www.aihw.gov.au/reports/heart-stroke-vascular-diseases/hsvd-facts/contents/about (accessed August 2024).

ENTRESTO PBS Information: Authority required (STREAMLINED) for chronic heart failure. Patients must be NYHA Class II-IV, have LVEF \leq 40% and be receiving optimal standard chronic heart failure treatment. Refer to PBS Schedule for full Authority Information.

For ENTRESTO Product Information, please [click here](#).

LEQVIO PBS Information: Authority Required (telephone/online) for patients with hypercholesterolaemia. Refer to PBS Schedule for full Authority information.

▼ LEQVIO is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

For LEQVIO Product Information, please [click here](#).

This content is intended for Australian healthcare professionals.

ENTRESTO® and the ENTRESTO® logo are registered trademarks of Novartis AG. LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG.

©2024 Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. For medical enquiries please contact 1800 671 203 or medinfo.phauno@novartis.com.

AU-26941. Ward7 NOEN33845M. September 2024.

